Nevertheless, YT revealed interesting anti-cancer properties, with a capacity to reduce the proliferation of estrogen receptor (ER)-positive MCF-7 breast cancer cells which were much more pronounced compared with the reference anticancer drug tamoxifen (IC50 = 0.62 and 14.43 μM for YT and tamoxifen, respectively (Figure 5). Here, ESR1 is linked to breast cancer.